

Section 1: Identification of the Substance/Mixture and of the Company/Undertaking

1.1 Product identifier	entifier
------------------------	----------

Product Name

• Kendex G043 OCTG

Synonyms

Grease, Lubricant, Thread Compound

1.2 Relevant identified uses of the substance or mixture and uses advised against Relevant identified use(s)
• Lubricant, long term rust and corrosion protection

1.3 Details of the supplier of the safety data sheet Manufacturer

• Topco Oilsite Products Ltd. Bay 7, 3401 - 19th Street N.E. Calgary, Alberta T2E 6S8 Canada www.topcooilsite.com msds@topcooilsite.com

Telephone (General) • 403-219-0255

1.4 Emergency telephone number

Manufacturer • 403-219-0255 Poison & Drug Information Service (Alberta Health Services) • 1-800-332-1414

Section 2: Hazards Identification

EU/EEC

According to: Regulation (EC) No 1272/2008 (CLP)/REACH 1907/2006 [amended by 2015/830]

2.1 Classification of the substance or mixture

CLP • Not classified

2.2 Label Elements

CLP

Hazard statements • No label element(s) required

2.3 Other Hazards

CLP

According to Regulation (EC) No. 1272/2008 (CLP) this material is not considered hazardous.

UN GHS Revision 4

According to: UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS): Fourth Revised Edition

2.1 Classification of the substance or mixture

• Hazardous to the aquatic environment Acute 3

2.2 Label elements

UN GHS	
Hazard statements	Harmful to aquatic life
Precautionary	
statements	
Prevention	 Avoid release to the environment.
Storage/Disposal	 Dispose of content and/or container in accordance with local, regional, national, and/or international regulations.
2.3 Other hazards	
UN GHS	 According to the Globally Harmonized System for Classification and Labeling (GHS) this product is considered hazardous
United States (US) According to: OSHA 29 CF	⁻ R 1910.1200 HCS
2.1 Classification of tl	he substance or mixture
OSHA HCS 2012	Not classified
2.2 Label elements	
OSHA HCS 2012	
Hazard statements	No label element(s) required
Precautionary statements	
Prevention	Wash thoroughly after handling. Wear protective gloves/protective clothing/eye protection/face protection.
2.3 Other hazards	
OSHA HCS 2012	¹ This product is not considered hazardous under the U.S. OSHA 29 CFR 1910.1200 Hazard Communication Standard.
Canada According to: WHMIS 2015	5
2.1 Classification of th	ne substance or mixture
2.2 Label elements WHMIS 2015	
Hazard statements • I Precautionary statements	No label element(s) required
2.3 Other hazards	
WHMIS 2015 •	n Canada, the product mentioned above is not considered hazardous under the Workplace Hazardous Materials Information System (WHMIS).

Section 3 - Composition/Information on Ingredients

• Material does not meet the criteria of a substance.

3.2 Mixtures

Composition						
Chemical Name	Identifiers	%	LD50/LC50	Classifications According to Regulation/Directive	Comments	
Mineral oil, petroleum distillates, solvent-dewaxed heavy paraffinic (mild or nosolvent-refining or hydrotreatment)	CAS:64742-65- 0 EC Number:265- 169-7 EU Index:649- 474-00-6	50% TO 70%	Ingestion/Oral-Rat LD50 • >5000 mg/kg Skin-Rabbit LD50 • >5000 mg/kg Inhalation-Rat LC50 • >5 mg/L 4 Hour(s)	EU CLP: Annex VI, Table 3.1: Carc. 1B, H350 UN GHS Revision 4: Not Classified OSHA HCS 2012: Not Classified WHMIS 2015: Not Classified	NDA	
Mineral oil, petroleum distillates, solvent-refined (mild) heavy paraffinic	CAS:64741-88- 4 EC Number:265- 090-8 EU Index:649- 454-00-7	10% TO 20%	Ingestion/Oral-Rat LD50 • >5000 mg/kg Skin-Rabbit LD50 • >2000 mg/kg	EU CLP: Annex VI, Table 3.1: Carc. 1B, H350 UN GHS Revision 4: Skin Irrit. 3; Asp. Tox. 2 OSHA HCS 2012: Not Classified WHMIS 2015: Not Classified	NDA	
Calcium monocarbonate	CAS: 471-34-1 EC Number: 207- 439-9	10% TO 20%	Ingestion/Oral-Rat LD50 • 6450 mg/kg	EU CLP: Skin Irrit. 2, H315; Eye Irrit. 2, H319 UN GHS Revision 4: Skin Irrit. 2; Eye Irrit. 2 OSHA HCS 2012: Skin Irrit. 2; Eye Irrit. 2 WHMIS 2015: Skin Irrit. 2; Eye Irrit. 2	NDA	
Sulfonic acid, petroleum, calcium salt	CAS: 61789-86-4 EINECS: 263-093-9	1% TO 5%	NDA	EU CLP: Not Classified UN GHS Revision 4: Not Classified OSHA HCS 2012: Not Classified WHMIS 2015: Not Classified	NDA	
Calcium alkylbenzene sulfonate	CAS :70024-69- 0 EINECS :274- 263-7	1% TO 5%	NDA	EU CLP: Not Classified UN GHS Revision 4: Not Classified OSHA HCS 2012: Not Classified WHMIS 2015: Not Classified	NDA	
Benzenesulfonic acid, C10-16-alkyl derivs., calcium salts	CAS :68584-23- 6 EINECS :271- 529-4	1% TO 5%	NDA	EU CLP: Not Classified UN GHS Revision 4: Not Classified OSHA HCS 2012: Not Classified WHMIS 2015: Not Classified	NDA	
Benzenesulfonic acid, dodecyl-, calcium salt	CAS: 26264-06-2 EINECS: 247-557-8	1% TO 3%	Ingestion/Oral-Rat LD50 • 1300 mg/kg	EU CLP: Acute Tox. 4, H302 UN GHS Revision 4: Acute Tox. 4 (orl); Aquatic Acute 2 OSHA HCS 2012: Acute Tox. 4 (orl) WHMIS 2015: Acute Tox. 4 (orl)	NDA	
2,6-Di-tert-butyl-p-cresol	CAS: 128-37-0 EC Number: 204- 881-4	0.1% TO 0.25%	Ingestion/Oral-Rat LD50 • 890 mg/kg	EU CLP: Acute Tox. 4, H302; Skin Irrit. 2, H315; Eye Irrit. 2, H319 UN GHS Revision 4: Acute Tox. 4 (Orl); Skin Irrit. 2; Eye Irrit. 2; Aquatic Acute 2 OSHA HCS 2012: Acute Tox. 4 (Orl); Skin Irrit. 2; Eye Irrit. 2 WHMIS 2015: Acute Tox. 4 (Orl); Skin Irrit. 2; Eye Irrit. 2	NDA	

See Section 16 for full text of H-statements.

Section 4 - First Aid Measures

4.1 Description of first aid measures

- Inhalation Move victim to fresh air. Administer oxygen if breathing is difficult. Give artificial respiration if victim is not breathing.
- Skin Wash skin with soap and water. Remove contaminated clothing and shoes. Get medical attention if symptoms occur.
- **Eye** In case of contact with substance, immediately flush eyes with running water for at least 20 minutes. If eye irritation persists: Get medical advice/attention.

Ingestion • Rinse mouth. Give plenty of water to drink. Obtain medical attention immediately if ingested.

4.2 Most important symptoms and effects, both acute and delayed

• Refer to Section 11 - Toxicological Information.

4.3 Indication of any immediate medical attention and special treatment needed

Notes to
 Physician
 All treatments should be based on observed signs and symptoms of distress in the patient.
 Consideration should be given to the possibility that overexposure to materials other than this product may have occurred.

Section 5 - Firefighting Measures

5.1 Extinguishing media

Suitable Extinguishing Media

Unsuitable Extinguishing Media

No data available

No data available

5.2 Special hazards arising from the substance or mixture

Unusual Fire and Explosion Hazards • Burning produces noxious and toxic fumes.

Hazardous Combustion Products

5.3 Advice for firefighters

• Structural firefighters' protective clothing will only provide limited protection. Wear positive pressure self-contained breathing apparatus (SCBA).

In case of fire use media as appropriate for surrounding fire.

Section 6 - Accidental Release Measures

6.1 Personal precautions, protective equipment and emergency procedures

- **Personal Precautions** Ventilate the area. Do not walk through spilled material. Wear appropriate personal protective equipment, avoid direct contact.
- **Emergency Procedures** Keep unauthorized personnel away. Stay upwind.

6.2 Environmental precautions

• Avoid run off to waterways and sewers.

6.3 Methods and material for containment and cleaning up

Containment/Clean-up
• Stop leak if you can do it without risk.
Carefully shovel or sweep up spilled n

Carefully shovel or sweep up spilled material and place in suitable container.

6.4 Reference to other sections

• Refer to Section 8 - Exposure Controls/Personal Protection and Section 13 - Disposal Considerations.

Section 7 - Handling and Storage

7.1 Precautions for safe handling

Handling • Use only with adequate ventilation. Keep away from heat and ignition sources. Use good safety and industrial hygiene practices. Wear appropriate personal protective equipment, avoid direct contact. Avoid contact with skin, eyes, and clothing. Do not eat, drink or smoke when using this product. Wash thoroughly with soap and water after handling and before eating, drinking, or using tobacco.

7.2 Conditions for safe storage, including any incompatibilities

Storage • Keep only in the original container. Keep container tightly closed. Store in a cool, dry, well-ventilated place.

7.3 Specific end use(s)

• Refer to Section 1.2 - Relevant identified uses.

Section 8 - Exposure Controls/Personal Protection

8.1 Control parameters

Exposure Limits/Guidelines						
	Result	ACGIH	Argentina	Australia	Canada Alberta	Canada British Columbia
2,6-Di-tert-butyl-p- cresol (128-37-0)	TWAs	2 mg/m3 TWA (inhalable fraction and vapor)	2 mg/m3 TWA [CMP] (inhalable fraction, aerosol and vapor)	10 mg/m3 TWA	10 mg/m3 TWA	2 mg/m3 TWA (aerosol, inhalable, and vapour)
Calcium monocarbonate (471-34-1)	TWAs	Not established	Not established	10 mg/m3 TWA (containing no asbestos and <1% crystalline silica, inhalable dust)	10 mg/m3 TWA	Not established
	•	E	xposure Limits/Gu	idelines (Con't.)		
	Result	Canada Manitoba	Canada New Brunswick	Canada Northwest Territories	Canada Nova Scotia	Canada Nunavut
2,6-Di-tert-butyl-p-	TWAs	2 mg/m3 TWA (inhalable fraction and vapor)	10 mg/m3 TWA	2 mg/m3 TWA (inhalable fraction and vapour)	2 mg/m3 TWA (inhalable fraction and vapor)	2 mg/m3 TWA (inhalable fraction and vapour)
(128-37-0)	STELs	Not established	Not established	4 mg/m3 STEL (inhalable fraction and vapour)	Not established	4 mg/m3 STEL (inhalable fraction and vapour)
Calcium	STELs	Not established	Not established	20 mg/m3 STEL (listed under Limestone)	Not established	20 mg/m3 STEL (listed under Limestone)
(471-34-1) TWAs Not establish		Not established	Not established	10 mg/m3 TWA (listed under Limestone)	Not established	10 mg/m3 TWA (listed under Limestone)
	•	E	xposure Limits/Gu	idelines (Con't.)		
	Result	Canada Ontario	Canada Quebec	Canada Saskatchewan	Canada Yukon	France
2,6-Di-tert-butyl-p-	TWAs	2 mg/m3 TWA (inhalable fraction and vapor)	Not established	2 mg/m3 TWA (inhalable fraction and vapour)	10 mg/m3 TWA	10 mg/m3 TWA [VME]
(128-37-0)	STELs	Not established	10 mg/m3 STEV	4 mg/m3 STEL (inhalable fraction and vapour)	20 mg/m3 STEL	Not established
Calcium	TWAs	Not established	10 mg/m3 TWAEV (total dust)	10 mg/m3 TWA (listed under Limestone)	30 mppcf TWA; 10 mg/m3 TWA	10 mg/m3 TWA [VME]
monocarbonate (471-34-1) STELs		Not established	Not established	20 mg/m3 STEL (listed under Limestone)	20 mg/m3 STEL	Not established
		E	xposure Limits/Gu	idelines (Con't.)	-	
	Result	Germany DFG	Germany TRGS	Indonesia	Israel	Malaysia
2,6-Di-tert-butyl-p- cresol (128-37-0)	TWAs	Not established	10 mg/m3 TWA AGW (The risk of damage to the embryo or fetus can be excluded when AGW and BGW values are observed, inhalable fraction, exposure factor 4)	10 mg/m3 TWA	2 mg/m3 TWA (inhalable fraction and vapor)	10 mg/m3 TWA

	Ceilings	40 mg/m3 Peak (can occur as vapor and aerosol at the same time, inhalable fraction)		Not established	Not established	Not establi	shed	Not established
	MAKs	10 mg/m3 T (can occur a and aeroso same time, fraction)	FWA MAK as vapor I at the inhalable	Not established	Not established	Not establi	shed	Not established
Sulfonic acid,	TWAs	Not establis	shed	5 mg/m3 TWA AGW (respirable fraction, exposure factor 4)	Not established	Not establi	shed	Not established
petroleum, calcium salt (61789-86-4)	Ceilings	20 mg/m3 F (respirable)	Peak fraction)	Not established	Not established	Not establi	shed	Not established
	MAKs	5 mg/m3 TWA MAK (respirable fraction)		Not established	Not established	Not establi	shed	Not established
			E>	posure Limits/Gu	idelines (Con't.)			
	Result	Mexi	со	NIOSH	OSHA Vacated	Port	ugal	Singapore
2.6-Di-tort-butyl-p-	STELs	20 mg/m3 S [PPT-CT]	TEL	Not established	Not established	Not establis	shed	Not established
cresol (128-37-0)	TWAs	10 mg/m3 TWA VLE- PPT		10 mg/m3 TWA	10 mg/m3 TWA	2 mg/m3 TWA [VLE- MP] (inhalable fraction, aerosol and vapor)		10 mg/m3 PEL
Calcium monocarbonate (471-34-1)	TWAs	Not established		10 mg/m3 TWA (total dust); 5 mg/m3 TWA (respirable dust)	Not established	10 mg/m3 ⁻ [VLE-MP] (matter cont Asbestos a Crystalline	TWA particulate taining no nd <1% silica)	Not established
			E>	posure Limits/Gu	idelines (Con't.)			
		Result	U	nited Kingdom	United States - C	California		Venezuela
2,6-Di-tert-butyl-p-c	resol	TWAs	10 mg/m	3 TWA	10 mg/m3 PEL		Not established	
(128-37-0) STELs 30 mg/m3		3 STEL (calculated)	Not established		Not establ	ished		
Calcium monocarbonate (471-34-1) TWAs Not estat		blished	5 mg/m3 PEL (respi fraction, listed under Particulates not other regulated); 10 mg/m dust, listed under Pa not otherwise regula	rable erwise 3 PEL (total articulates ted)	10 mg/m3	TWA [VTRE-L-8/40		

Exposure Control Notations

Mexico

•2,6-Di-tert-butyl-p-cresol (128-37-0): Carcinogens: (A4 - Not classifiable as a human carcinogen)

Egypt

•Calcium monocarbonate (471-34-1): Nuisance Dusts: (10 mg/m3 TWA (containing <1% Quartz, total dust); 30 mppcf TWA (containing <1% Quartz, total dust); 3 mg/m3 TWA (containing <1% Quartz, inhalable dust))

Portugal

•2,6-Di-tert-butyl-p-cresol (128-37-0): Carcinogens: (A4 - Not Classifiable as a Human Carcinogen) Indonesia

•2,6-Di-tert-butyl-p-cresol (128-37-0): **Carcinogens:** (A4 - not classifiable as a human carcinogen) **Argentina**

•2,6-Di-tert-butyl-p-cresol (128-37-0): **Carcinogens:** (A4 - Not classifiable as a human carcinogen) **Canada Manitoba**

•2,6-Di-tert-butyl-p-cresol (128-37-0): Carcinogens: (A4 Not Classifiable as a Human Carcinogen) Canada New Brunswick

•2,6-Di-tert-butyl-p-cresol (128-37-0): **Carcinogens:** (A4 - Not Classifiable as a Human Carcinogen) **Canada Nova Scotia**

•2,6-Di-tert-butyl-p-cresol (128-37-0): Carcinogens: (A4 - Not Classifiable as a Human Carcinogen) Venezuela

•2,6-Di-tert-butyl-p-cresol (128-37-0): Ceilings: (Present)

ACGIH

•2,6-Di-tert-butyl-p-cresol (128-37-0): Carcinogens: (A4 - Not Classifiable as a Human Carcinogen)

Germany DFG

•Sulfonic acid, petroleum, calcium salt (61789-86-4): Pregnancy: (classification not yet possible (respirable fraction))

•2,6-Di-tert-butyl-p-cresol (128-37-0): Carcinogens: (Category 4 (no significant contribution to human cancer)) | Pregnancy: (no risk to embryo/fetus if exposure limits adhered to)

Exposure Limits Supplemental ACGIH

•2,6-Di-tert-butyl-p-cresol (128-37-0): TLV Basis - Critical Effects: (upper respiratory tract irritation)

8.2 Exposure controls

- Engineering Measures/Controls
 Good general ventilation should be used. Ventilation rates should be matched to conditions. If applicable, use process enclosures, local exhaust ventilation, or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels to an acceptable level.
 Personal Protective Equipment

 In case of insufficient ventilation, wear suitable respiratory equipment.
 Wear protective eyewear (goggles, face shield, or safety glasses).
- **Skin/Body** Polyvinyl alcohol or nitrile- butyl-rubber gloves. Wear long sleeves and/or protective coveralls.
- **Environmental Exposure Controls** • Controls should be engineered to prevent release to the environment, including procedures to prevent spills, atmospheric release and release to waterways. Follow best practice for site management and disposal of waste.

Key to abbreviations

ACGIH = American Conference of Governmental Industrial Hygiene	STEL	= Short Term Exposure Limits are based on 15-minute exposures
MAK = Maximale Arbeitsplatz Konzentration is the maximum permissible concentration	STEV	= Short Term Exposure Value
NIOSH = National Institute of Occupational Safety and Health	TLV	= Threshold Limit Value determined by the American Conference of Governmental Industrial Hygienists (ACGIH)
OSHA = Occupational Safety and Health Administration	TWA	= Time-Weighted Averages are based on 8h/day, 40h/week exposures
PEL = Permissible Exposure Level determined by the Occupational Safety and Health Administration (OSHA)	TWAEV	= Time-Weighted Average Exposure Value

Section 9 - Physical and Chemical Properties

9.1 Information on Basic Physical and Chemical Properties

Material Description

Matchai Description			
Physical Form	Solid	Appearance/Description	Orange semi-solid smooth paste with mild petroleum odor.
Color	Orange	Odor	Mild, petroleum.
Odor Threshold	Data lacking		
General Properties			
Boiling Point	Data lacking	Melting Point/Freezing Point	Data lacking
Decomposition Temperature	Data lacking	pН	Data lacking
Specific Gravity/Relative Density	Data lacking	Density	0.95 to 1.05 g/mL
Water Solubility	Data lacking	Viscosity	15 to 25 Centipoise (cPs, cP) or mPas
Explosive Properties	Data lacking	Oxidizing Properties:	Data lacking
Volatility			
Vapor Pressure	Data lacking	Vapor Density	Data lacking
Evaporation Rate	Data lacking		
Flammability			
Flash Point	> 180 °C(> 356 °F) COC (Cleveland Open Cup)	UEL	Data lacking
LEL	Data lacking	Autoignition	Data lacking
Flammability (solid, gas)	Data lacking		
Environmental			
Octanol/Water Partition coefficient	Data lacking		

9.2 Other Information

• No additional physical and chemical parameters noted.

Section 10: Stability and Reactivity

10.1 Reactivity

• No dangerous reaction known under conditions of normal use.

10.2 Chemical stability

• Stable under normal temperatures and pressures.

10.3 Possibility of hazardous reactions

• Hazardous polymerization will not occur.

10.4 Conditions to avoid

• Keep away from heat, sparks and flame.

10.5 Incompatible materials

• None in particular.

10.6 Hazardous decomposition products

• Hazardous decomposition products formed under fire conditions: Carbon oxides.

Section 11 - Toxicological Information

11.1 Information on toxicological effects

		Components
Mineral oil, petroleum distillates, solvent-dewaxed heavy paraffinic (mild or nosolvent- refining or hydrotreatment) (50% TO 70%)	64742- 65-0	Acute Toxicity: Ingestion/Oral-Rat LD50 • >5000 mg/kg; Skin-Rabbit LD50 • >5000 mg/kg; Tumorigen / Carcinogen: Skin-Mouse • 389 g/kg 78 Week(s)-Intermittent; <i>Tumorigenic</i> :Equivocal tumorigenic agent by RTECS criteria; Skin and Appendages:Other.Tumors; Tumorigenic:Tumors at site of application; Skin-Mouse TDLo • 386 g/kg 22 Week(s)-Intermittent; Tumorigenic:Equivocal tumorigenic agent by RTECS criteria; Skin and Appendages:Other.Tumors; Tumorigenic:Tumors at site of application
Calcium monocarbonate (10% TO 20%)	471-34- 1	Acute Toxicity: Ingestion/Oral-Rat LD50 • 6450 mg/kg; Irritation: Eye-Rabbit • 750 µg 24 Hour(s) • Severe irritation; Skin-Rabbit • 500 mg 24 Hour(s) • Moderate irritation; Multi-dose Toxicity: Ingestion/Oral-Woman TDLo • 4.08 g/kg 30 Day(s)-Intermittent; <i>Vascular</i> :BP elevation not characterized in autonomic section; <i>Gastrointestinal</i> :Changes in structure or function of endocrine pancreas; <i>Biochemical:Metabolism (intermediary)</i> :Effect on inflammation or mediation of inflammation
Benzenesulfonic acid, dodecyl-, calcium salt (1% TO 3%)	26264- 06-2	Acute Toxicity: Ingestion/Oral-Rat LD50 • 1300 mg/kg
Sulfonic acid, petroleum, calcium salt (1% TO 5%)	61789- 86-4	Acute Toxicity: Ingestion/Oral-Rat LD50 • >5 g/kg; Gastrointestinal:Hypermotility, diarrhea; Skin-Rabbit LD50 • >5 g/kg
2,6-Di-tert-butyl-p-cresol (0.1% TO 0.25%)	128-37- 0	Acute Toxicity: Ingestion/Oral-Rat LD50 • 890 mg/kg; Ingestion/Oral-Rat TDLo • 25 mg/kg; <i>Blood</i> : Changes in serum composition (e.g., TP, bilirubin cholesterol); <i>Biochemical:Enzyme</i> <i>inhibition, induction, or change in blood or tissue levels</i> : Transaminases; <i>Biochemical:Enzyme</i> <i>inhibition, induction, or change in blood or tissue levels</i> : Other enzymes; Ingestion/Oral-Woman TDLo • 80 mg/kg; <i>Behavioral</i> : Coma; <i>Gastrointestinal</i> : Gastritis; <i>Gastrointestinal</i> : Nausea or vomiting; Irritation: Eye-Rabbit • 100 mg 24 Hour(s) • Moderate irritation; Skin-Rabbit • 500 mg 48 Hour(s) • Moderate irritation; Multi-dose Toxicity: Ingestion/Oral-Rat TDLo • 6.3 mg/kg 1 Week(s)-Continuous; <i>Brain and</i> <i>Coverings</i> : Changes in circulation (Hemorrhage, thrombosis, etc.); <i>Blood</i> : Hemorrhage; <i>Related to Chronic Data</i> : Death in the Other Multiple Dose data type field; Ingestion/Oral-Rat TDLo • 39.7 mg/kg 3 Day(s)-Intermittent; <i>Blood</i> : Change in clotting factors; Ingestion/Oral-Rat TDLo • 2.625 mg/kg 1 Week(s)-Continuous; <i>Liver</i> : Other changes; <i>Blood</i> : Change in clotting factors; <i>Biochemical:Enzyme inhibition, induction, or change in blood or tissue levels</i> : Multiple enzyme effects; Mutagen: Other mutation test systems • Ingestion/Oral-Mouse • 500 mg/kg; Dominant lethal test • Ingestion/Oral-Mouse • 12 g/kg 10 Week(s)-Continuous; Dominant lethal test • Ingestion/Oral-Rat * Ingestion/Oral-Mouse • 12 g/kg 10 Week(s)-Continuous; Dominant lethal test • Ingestion/Oral-Rat * Ingestion/Oral-Mouse • 12 g/kg 10 Week(s)-Continuous; Dominant lethal test • Ingestion/Oral-Rat * Ingestion/Oral-Mouse • 12 g/kg 10 Week(s)-Continuous; Dominant lethal test • Ingestion/Oral-Rat * S460 mg/kg 10 Week(s)-Continuous; Reproductive: Ingestion/Oral-Mouse TDLo • 43800 mg/kg (52D pre/1-21D preg); <i>Reproductive</i> <i>Effects:Maternal Effects</i> :Parturition; <i>Reproductive Effects:Effects on Newborn</i> :Weaning or Iactation index; <i>Reproductive Effects:Effects on Newborn</i> :Growth statistics (e.g., reduced)

wei De Tur Tur Yea Effe Mo crit TD Tho spo	ight gain); Ingestion/Oral-Mouse TDLo • 1200 mg/kg (9D preg); <i>Reproductive Effects:Specific velopmental Abnormalities</i> :Musculoskeletal system; morigen / Carcinogen: Ingestion/Oral-Mouse • 1423 mg/kg 43 Week(s)-Continuous; <i>morigenic</i> :Neoplastic by RTECS criteria; <i>Liver</i> :Tumors; Ingestion/Oral-Rat • 247 g/kg 3 ar(s)-Continuous; <i>Tumorigenic</i> :Carcinogenic by RTECS criteria; <i>Reproductive</i> <i>ects:Tumorigenic Effects</i> :Transplacental tumorigenesis; <i>Liver</i> :Tumors; Ingestion/Oral- use TDLo • 435 mg/kg 69 Week(s)-Continuous; <i>Tumorigenic</i> :Carcinogenic by RTECS teria; <i>Lungs, Thorax, or Respiration</i> :Tumors; <i>Gastrointestinal</i> :Tumors; Ingestion/Oral-Mouse Lo • 1200 mg/kg 3 Week(s)-Intermittent; <i>Tumorigenic</i> :Neoplastic by RTECS criteria; <i>Lungs,</i> <i>forax, or Respiration</i> :Tumors; <i>Tumorigenic</i> :Tumors after systemic administration not seen pontaneously
--	--

GHS Properties	Classification	
Acute toxicity	EU/CLP•Data lacking UN GHS 4•Data lacking OSHA HCS 2012•Data lacking WHMIS 2015•Data lacking	
Skin corrosion/Irritation	EU/CLP•Data lacking UN GHS 4•Data lacking OSHA HCS 2012•Data lacking WHMIS 2015•Data lacking	
Serious eye damage/Irritation	EU/CLP•Data lacking UN GHS 4•Data lacking OSHA HCS 2012•Data lacking WHMIS 2015•Data lacking	
Skin sensitization	EU/CLP•Data lacking UN GHS 4•Data lacking OSHA HCS 2012•Data lacking WHMIS 2015•Data lacking	
Respiratory sensitization	EU/CLP•Data lacking UN GHS 4•Data lacking OSHA HCS 2012•Data lacking WHMIS 2015•Data lacking	
Aspiration Hazard	EU/CLP•Data lacking UN GHS 4•Data lacking OSHA HCS 2012•Data lacking WHMIS 2015•Data lacking	
Carcinogenicity	EU/CLP•Data lacking UN GHS 4•Data lacking OSHA HCS 2012•Data lacking WHMIS 2015•Data lacking	
Germ Cell Mutagenicity	EU/CLP•Data lacking UN GHS 4•Data lacking OSHA HCS 2012•Data lacking WHMIS 2015•Data lacking	
Toxicity for Reproduction	EU/CLP•Data lacking UN GHS 4•Data lacking OSHA HCS 2012•Data lacking WHMIS 2015•Data lacking	
STOT-SE	EU/CLP•Data lacking UN GHS 4•Data lacking OSHA HCS 2012•Data lacking WHMIS 2015•Data lacking	
STOT-RE	EU/CLP•Data lacking UN GHS 4•Data lacking	

	OSHA HCS 2012•Data lacking
	WHMIS 2015•Data lacking
Potential Health Effects	
Inhalation	
Acute (Immediate) • Under normal conditions of	of use, no health effects are expected.
Chronic (Delayed) • No data available	
Skin	
Acute (Immediate) • Under normal conditions of	of use, no health effects are expected.
Chronic (Delayed) • No data available	
Eye	
Acute (Immediate) • Under normal conditions of	of use, no health effects are expected.
Chronic (Delayed) • No data available	
Ingestion	
Acute (Immediate) • Under normal conditions of	of use, no health effects are expected.
Chronic (Delayed) • No data available	
Kay to approviations	

Key to abbreviations

LD = Lethal Dose TD = Toxic Dose

Section 12 - Ecological Information

12.1 Toxicity

• Harmful to aquatic life.

12.2 Persistence and degradability

• Material data lacking.

12.3 Bioaccumulative potential

• Material data lacking.

12.4 Mobility in Soil

• Material data lacking.

12.5 Results of PBT and vPvB assessment

• No PBT and vPvB assessment has been conducted.

12.6 Other adverse effects

• No studies have been found.

Section 13 - Disposal Considerations

13.1 Waste treatment methods

Product waste	 Dispose of content and/or container in accordance with local, regional, national, and/or international regulations.
Packaging	• Dispose of content and/or container in accordance with local, regional, national, and/or
waste	international regulations.

Section 14 - Transport Information

14.1 UN	14.2 UN proper	14.3 Transport hazard	14.4 Packing	14.5 Environmental
number	shipping name	class(es)	group	hazards

DOT	Not Applicable	Not Regulated	Not Applicable	Not Applicable	NDA
TDG	Not Applicable	Not Regulated	Not Applicable	Not Applicable	NDA
IMO/IMDG	Not Applicable	Not Regulated	Not Applicable	Not Applicable	NDA
IATA/ICAO	Not Applicable	Not Regulated	Not Applicable	Not Applicable	NDA

14.6 Special precautions for user

• None specified.

•

Acute

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code • Data lacking.

Section 15 - Regulatory Information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

SARA Hazard Classifications

State Right To Know Component CAS PA 2,6-Di-tert-butyl-p-128-37-0 Yes cresol Benzenesulfonic acid, C10-16-alkyl 68584-23-No derivs., calcium salts Benzenesulfonic 26264-06acid, dodecyl-, Yes 2 calcium salt Calcium 70024-69alkylbenzene No sulfonate Calcium 471-34-1 No monocarbonate Mineral oil, petroleum distillates, solvent-64742-65-No dewaxed heavy paraffinic (mild or nosolvent-refining or hydrotreatment) Mineral oil, petroleum 64741-88distillates, solvent-No Δ refined (mild) heavy paraffinic Sulfonic acid, 61789-86-No petroleum, calcium salt

Inventory						
Component	CAS	Australia AICS	Canada DSL	Canada NDSL	China	EU EINECS
2,6-Di-tert-butyl-p- cresol	128-37-0	Yes	Yes	No	Yes	Yes
Benzenesulfonic acid, C10-16-alkyl derivs., calcium salts	68584-23- 6	Yes	Yes	No	Yes	Yes
Benzenesulfonic acid, dodecyl-, calcium salt	26264-06- 2	Yes	Yes	No	Yes	Yes
Calcium alkylbenzene sulfonate	70024-69- 0	Yes	Yes	No	Yes	Yes
Calcium monocarbonate	471-34-1	Yes	Yes	No	Yes	Yes

Mineral oil, petroleum distillates, solvent- dewaxed heavy paraffinic (mild or nosolvent-refining or hydrotreatment)	l oil, um ues, solvent- ed heavy nic (mild or ent-refining rotreatment)		Yes		Yes	No		Yes		Yes
Mineral oil, petroleum distillates, solvent- refined (mild) heavy paraffinic	t- 64741-88- 4		Yes		Yes	No	D	Yes		Yes
Sulfonic acid, petroleum, calcium salt	61789-86- 4		Yes		Yes	No	0	Yes		Yes
Inventory (Con't.)										
Component			CAS		EU ELNICS		Japan EN	CS	TSCA	
2,6-Di-tert-butyl-p-c	resol	128-	37-0	No		Yes			Yes	
Benzenesulfonic acid, C10- 16-alkyl derivs., calcium salts		6858	34-23-6	No	No			Yes		
Benzenesulfonic acid, dodecyl-, calcium salt		2626	64-06-2	No			Yes		Yes	
Calcium alkylbenzene sulfonate		7002	24-69-0	No	٩٥		Yes		Yes	
Calcium monocarbonate		471-	34-1	No			Yes		Yes	
Mineral oil, petroleum distillates, solvent-dewaxed heavy paraffinic (mild or nosolvent-refining or hydrotreatment)		6474	42-65-0	No			No		Yes	
Mineral oil, petroleum distillates, solvent-refined (mild) heavy paraffinic		6474	41-88-4	No			No		Yes	
Sulfonic acid, petroleum, calcium salt		6178	39-86-4	No			Yes		Yes	

United States - California

Environment

U.S California - Proposition 65 - Carcinogens List		
•Sulfonic acid, petroleum, calcium salt	61789-86-4	Not Listed
•2,6-Di-tert-butyl-p-cresol	128-37-0	Not Listed
Calcium monocarbonate	471-34-1	Not Listed
Calcium alkylbenzene sulfonate	70024-69-0	Not Listed
 Benzenesulfonic acid, C10-16-alkyl derivs., calcium salts 	68584-23-6	Not Listed
 Benzenesulfonic acid, dodecyl-, calcium salt 	26264-06-2	Not Listed
•Mineral oil, petroleum distillates, solvent-dewaxed heavy paraffinic (mild or nosolvent- refining or hydrotreatment)	64742-65-0	Not Listed
 Mineral oil, petroleum distillates, solvent-refined (mild) heavy paraffinic 	64741-88-4	Not Listed
U.S California - Proposition 65 - Developmental Toxicity		
•Sulfonic acid, petroleum, calcium salt	61789-86-4	Not Listed
•2,6-Di-tert-butyl-p-cresol	128-37-0	Not Listed
Calcium monocarbonate	471-34-1	Not Listed
Calcium alkylbenzene sulfonate	70024-69-0	Not Listed
 Benzenesulfonic acid, C10-16-alkyl derivs., calcium salts 	68584-23-6	Not Listed
 Benzenesulfonic acid, dodecyl-, calcium salt 	26264-06-2	Not Listed
•Mineral oil, petroleum distillates, solvent-dewaxed heavy paraffinic (mild or nosolvent- refining or hydrotreatment)	64742-65-0	Not Listed
 Mineral oil, petroleum distillates, solvent-refined (mild) heavy paraffinic 	64741-88-4	Not Listed
U.S California - Proposition 65 - Maximum Allowable Dose Levels (MADL)		
•Sulfonic acid, petroleum, calcium salt	61789-86-4	Not Listed
•2,6-Di-tert-butyl-p-cresol	128-37-0	Not Listed
Calcium monocarbonate	471-34-1	Not Listed

Calcium alkylbenzene sulfonate	70024-69-0	Not Listed
•Benzenesulfonic acid, C10-16-alkyl derivs., calcium salts	68584-23-6	Not Listed
 Benzenesulfonic acid, dodecyl-, calcium salt 	26264-06-2	Not Listed
•Mineral oil, petroleum distillates, solvent-dewaxed heavy paraffinic (mild or nosolvent-	64742 65 0	Not Listed
refining or hydrotreatment)	04742-05-0	NUL LISIEU
 Mineral oil, petroleum distillates, solvent-refined (mild) heavy paraffinic 	64741-88-4	Not Listed
U.S California - Proposition 65 - No Significant Risk Levels (NSRL)		
 Sulfonic acid, petroleum, calcium salt 	61789-86-4	Not Listed
•2,6-Di-tert-butyl-p-cresol	128-37-0	Not Listed
•Calcium monocarbonate	471-34-1	Not Listed
Calcium alkylbenzene sulfonate	70024-69-0	Not Listed
 Benzenesulfonic acid, C10-16-alkyl derivs., calcium salts 	68584-23-6	Not Listed
 Benzenesulfonic acid, dodecyl-, calcium salt 	26264-06-2	Not Listed
•Mineral oil, petroleum distillates, solvent-dewaxed heavy paraffinic (mild or nosolvent- refining or hydrotreatment)	64742-65-0	Not Listed
•Mineral oil, petroleum distillates, solvent-refined (mild) heavy paraffinic	64741-88-4	Not Listed
U.S California - Proposition 65 - Reproductive Toxicity - Female		
•Sulfonic acid, petroleum, calcium salt	61789-86-4	Not Listed
•2,6-Di-tert-butyl-p-cresol	128-37-0	Not Listed
Calcium monocarbonate	471-34-1	Not Listed
Calcium alkylbenzene sulfonate	70024-69-0	Not Listed
 Benzenesulfonic acid, C10-16-alkyl derivs., calcium salts 	68584-23-6	Not Listed
 Benzenesulfonic acid, dodecyl-, calcium salt 	26264-06-2	Not Listed
•Mineral oil, petroleum distillates, solvent-dewaxed heavy paraffinic (mild or nosolvent- refining or hydrotreatment)	64742-65-0	Not Listed
 Mineral oil, petroleum distillates, solvent-refined (mild) heavy paraffinic 	64741-88-4	Not Listed
U.S California - Proposition 65 - Reproductive Toxicity - Male		
•Sulfonic acid, petroleum, calcium salt	61789-86-4	Not Listed
•2,6-Di-tert-butyl-p-cresol	128-37-0	Not Listed
Calcium monocarbonate	471-34-1	Not Listed
Calcium alkylbenzene sulfonate	70024-69-0	Not Listed
 Benzenesulfonic acid, C10-16-alkyl derivs., calcium salts 	68584-23-6	Not Listed
 Benzenesulfonic acid, dodecyl-, calcium salt 	26264-06-2	Not Listed
•Mineral oil, petroleum distillates, solvent-dewaxed heavy paraffinic (mild or nosolvent- refining or hydrotreatment)	64742-65-0	Not Listed
•Mineral oil, petroleum distillates, solvent-refined (mild) heavy paraffinic	64741-88-4	Not Listed

15.2 Chemical Safety Assessment

• No Chemical Safety Assessment has been carried out.

Section 16 - Other Information

Relevant Phrases (code & full text)

	 H302 - Harmful if swallowed H315 - Causes skin irritation H319 - Causes serious eye irritation H350 - May cause cancer.
Revision Date	21/September/2017
Last Revision Date	• 03/August/2017
Preparation Date	• 03/August/2017
Disclaimer/Statement of Liability	 The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.
Key to abbreviations	

Key to abbreviations NDA = No Data Available